Oxybenzone
Explore a selection of our essential drug information below, or:
Identification
- Summary
Oxybenzone is a sunscreen agent found in sunscreens that absorbs UV rays.
- Brand Names
- Meijer
- Generic Name
- Oxybenzone
- DrugBank Accession Number
- DB01428
- Background
Oxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone. It forms colorless crystals that are readily soluble in most organic solvents. It is used as an ingredient in sunscreen and other cosmetics because it absorbs UV-A ultraviolet rays.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
- Weight
- Average: 228.2433
Monoisotopic: 228.07864425 - Chemical Formula
- C14H12O3
- Synonyms
- 2-Benzoyl-5-methoxyphenol
- 2-Hydroxy-4-methoxybenzophenone
- 4-Methoxy-2-hydroxybenzophenone
- Benzophenone-3
- Oxibenzona
- Oxybenzone
- Oxybenzonum
- External IDs
- NSC-7778
Pharmacology
- Indication
Used as an ingredient in sunscreen and other cosmetics.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Oxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone.
- Mechanism of action
Oxybenzone absorbs UV-A ultraviolet rays, preventing them from reaching the skin.
Target Actions Organism AHormone-sensitive lipase inhibitorHumans NProgesterone receptor antagonistHumans NAndrogen receptor antagonistHumans NEstrogen receptor Not Available Humans NEstrogen receptor beta Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
In vivo studies show oxybenzone is abosorbed transdermally (through the skin) and is excreted in the urine.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Oxybenzone which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Oxybenzone which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Oxybenzone which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Oxybenzone which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Oxybenzone which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Active Moieties
Name Kind UNII CAS InChI Key Benzophenone unknown 701M4TTV9O 119-61-9 RWCCWEUUXYIKHB-UHFFFAOYSA-N - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bebak Baby Sun Lotion 17 g/200g Topical SORA KOZMETIK SANAYI TICARET ANONIM SIRKETI 2020-07-16 Not applicable US Zep Sun Screen Towels Liquid 0.05 g/100g Topical Zep, Inc 2013-05-01 2020-01-02 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 100 SPF Cream Oxybenzone (6 % w/w) + Avobenzone (3 % w/w) + Homosalate (15 % w/w) + Octisalate (5 % w/w) + Octocrylene (10 % w/w) Cream Topical Vital Science A Div. Of/Une Div. De Valeant Canada Ltd/Ltee 2010-06-03 2014-08-27 Canada 1177, 1178 Sunscreen Oxybenzone (5 g/100g) + Homosalate (6 g/100g) + Octinoxate (7.5 g/100g) + Octisalate (5 g/100g) Cream Topical Dynarex Corporation 2021-05-27 Not applicable US 14-day Skin Rescue SPF 30 Oxybenzone (6 % w/w) + Avobenzone (3 % w/w) + Homosalate (4 % w/w) + Octisalate (5 % w/w) + Octocrylene (2.35 % w/w) Cream Topical Johnson & Johnson 2009-02-16 2013-07-31 Canada 15 SPF Fps Premium Sunscreen Oxybenzone (2 % w/w) + Avobenzone (3 % w/w) + Ensulizole (2 % w/w) + Octocrylene (10 % w/w) Lotion Topical Empack Spraytech Inc 2005-05-04 2021-08-10 Canada 15 SPF Fps Sunscreen Lotion Écran Solaire Oxybenzone (3.0 % w/w) + Avobenzone (0.9 % w/w) + Octocrylene (3.0 % w/w) Lotion Topical Energizer Canada Inc 2007-03-01 2011-07-29 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 4362 First Aid Kit Oxybenzone (6 g/100mL) + Ammonia (0.045 g/0.3mL) + Avobenzone (1 g/100mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Ethanol (0.5 mL/1mL) + Homosalate (5 g/100mL) + Hydrocortisone acetate (1 g/100g) + Isopropyl alcohol (0.7 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Neomycin sulfate (3.5 mg/1g) + Octinoxate (7.5 g/100mL) + Octisalate (5 g/100mL) + Polymyxin B sulfate (5000 [iU]/1g) + Povidone-iodine (10 mg/1mL) + Water (98.6 mL/100mL) Kit Ophthalmic; Respiratory (inhalation); Topical Honeywell Safety Products USA, Inc 2018-09-13 Not applicable US Alphaquin HP Oxybenzone (50 mg/1g) + Hydroquinone (40 mg/1g) + Octinoxate (75 mg/1g) Cream Topical Stratus Pharmaceuticals 1993-01-01 2017-02-01 US CoreTex Professional Outdoor Skin Protection Wallet Oxybenzone (6 g/100mL) + Oxybenzone (6 g/100g) + Oxybenzone (6 g/100mL) + Avobenzone (1 g/100mL) + Avobenzone (1 g/100g) + Avobenzone (3 g/100mL) + Benzocaine (6 g/100mL) + Diphenhydramine hydrochloride (2 g/100mL) + Ethanol (62.5 mL/100mL) + Homosalate (5 g/100mL) + Homosalate (5 g/100g) + Homosalate (7.5 g/100mL) + Octinoxate (7.5 g/100mL) + Octinoxate (7.5 g/100g) + Octisalate (5 g/100mL) + Octisalate (5 g/100g) + Octisalate (5 g/100mL) + Octocrylene (2.5 g/100mL) + Synthetic camphor (0.1 g/100mL) + Zinc acetate dihydrate (1 g/100mL) Gel; Kit; Lipstick; Liquid; Lotion; Swab Topical CoreTex Products Inc 2019-11-27 Not applicable US CoreTex Professional Outdoor Skin Protection Wallet Oxybenzone (6 g/100mL) + Oxybenzone (6 g/100g) + Oxybenzone (6 g/100mL) + Avobenzone (1 g/100mL) + Avobenzone (1 g/100g) + Avobenzone (3 g/100mL) + Benzocaine (6 g/100mL) + Diphenhydramine hydrochloride (2 g/100mL) + Ethanol (62.5 mL/100mL) + Homosalate (5 g/100mL) + Homosalate (5 g/100g) + Homosalate (7.5 g/100mL) + Octinoxate (7.5 g/100mL) + Octinoxate (7.5 g/100g) + Octisalate (5 g/100mL) + Octisalate (5 g/100g) + Octisalate (5 g/100mL) + Octocrylene (2.5 g/100mL) + Synthetic camphor (0.1 g/100mL) + Zinc acetate dihydrate (1 g/100mL) Gel; Kit; Lipstick; Liquid; Lotion; Swab Topical CoreTex Products Inc 2019-11-27 Not applicable US CoreTex Professional Outdoor Skin Protection Wallet Oxybenzone (6 g/100mL) + Oxybenzone (6 g/100g) + Oxybenzone (6 g/100mL) + Avobenzone (1 g/100mL) + Avobenzone (1 g/100g) + Avobenzone (3 g/100mL) + Benzocaine (6 g/100mL) + Diphenhydramine hydrochloride (2 g/100mL) + Ethanol (62.5 mL/100mL) + Homosalate (5 g/100mL) + Homosalate (5 g/100g) + Homosalate (7.5 g/100mL) + Octinoxate (7.5 g/100mL) + Octinoxate (7.5 g/100g) + Octisalate (5 g/100mL) + Octisalate (5 g/100g) + Octisalate (5 g/100mL) + Octocrylene (2.5 g/100mL) + Synthetic camphor (0.1 g/100mL) + Zinc acetate dihydrate (1 g/100mL) Gel; Kit; Lipstick; Liquid; Lotion; Swab Topical CoreTex Products Inc 2019-11-27 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzophenones
- Direct Parent
- Benzophenones
- Alternative Parents
- Diphenylmethanes / Aryl-phenylketones / Methoxyphenols / Phenoxy compounds / Methoxybenzenes / Benzoyl derivatives / Anisoles / Alkyl aryl ethers / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids show 3 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Alkyl aryl ether / Anisole / Aromatic homomonocyclic compound / Aryl ketone / Aryl-phenylketone / Benzophenone / Benzoyl / Diphenylmethane show 12 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- monomethoxybenzene, hydroxybenzophenone (CHEBI:34283)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 95OOS7VE0Y
- CAS number
- 131-57-7
- InChI Key
- DXGLGDHPHMLXJC-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H12O3/c1-17-11-7-8-12(13(15)9-11)14(16)10-5-3-2-4-6-10/h2-9,15H,1H3
- IUPAC Name
- 2-benzoyl-5-methoxyphenol
- SMILES
- COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1
References
- General References
- Gonzalez H, Farbrot A, Larko O, Wennberg AM: Percutaneous absorption of the sunscreen benzophenone-3 after repeated whole-body applications, with and without ultraviolet irradiation. Br J Dermatol. 2006 Feb;154(2):337-40. [Article]
- External Links
- Human Metabolome Database
- HMDB0015497
- KEGG Drug
- D05309
- KEGG Compound
- C14285
- PubChem Compound
- 4632
- PubChem Substance
- 46508419
- ChemSpider
- 4471
- BindingDB
- 50253134
- 32673
- ChEBI
- 34283
- ChEMBL
- CHEMBL1625
- ZINC
- ZINC000000136138
- PharmGKB
- PA164742933
- Wikipedia
- Oxybenzone
- MSDS
- Download (73.7 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Active Not Recruiting Treatment Photodamaged Skin / Volume Deficiency of the Midface 1 somestatus stop reason just information to hide Not Available Completed Not Available Acne, Adult 1 somestatus stop reason just information to hide Not Available Completed Not Available Arousal Disorders, Sexual / Dyspareunia (Female Excluding Psychogenic) / Hypoactive Sexual Desire Disorder (HSDD) / Hypoestrogenism / Menopause related conditions / Vulvovaginal Disease 1 somestatus stop reason just information to hide Not Available Completed Not Available Type 2 Diabetes Mellitus 1 somestatus stop reason just information to hide Not Available Completed Basic Science Microbiota 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Axia Medical Solutions LLC
- Beaura SPA Parker Center
- Body Sculpting Center
- Cosmetic Laser Skin Care
- Dermatech
- Dulles Cosmetic Surgery and Skin Care Center
- Fairfield County Plastic Surgery
- Genesis Pharmaceutical Inc.
- Legacy Pharmaceuticals Packaging LLC
- Obagi Medical Products Inc.
- Paul Goco MD
- Plastic Surgery Associates PC
- Puretek Corp.
- Qualitest
- River's Edge Pharmaceuticals
- Rulian Md Peter
- Schooler Medical Professionals
- Sheffield Laboratories Div Faria Limited LLC
- Sonar Products Inc.
- Stratus Pharmaceuticals Inc.
- Taro Pharmaceuticals USA
- Thao MD David
- Truett Laboratories
- Valeant Ltd.
- Dosage Forms
Form Route Strength Kit Ophthalmic; Respiratory (inhalation); Topical Salve Topical Lotion Topical 17 g/200g Ointment Topical Kit Oral; Topical Paste Topical Kit; ointment; stick Topical Kit Topical Cloth; cream Topical Kit; salve Topical Gel Topical Stick Oral Solution Topical Gel; kit; lotion Topical Gel; kit; lipstick; liquid; lotion; swab Topical Liquid; lotion Topical Jelly Topical Oil Topical Cream Topical Cream, augmented Topical Liquid Topical Suspension Topical Powder Topical Lotion / shampoo Topical Kit; stick Topical Kit; ointment Topical Lipstick Topical Cream; kit Topical Emulsion Topical Cream; kit; lotion Topical Kit; lotion Topical Lotion Cutaneous Aerosol Topical Spray, suspension Topical Spray Oral Stick Topical Spray Topical Lotion Topical Liquid; spray Topical Lotion Oral Cloth Topical Kit; liquid Topical Lotion; spray Topical Aerosol, foam Topical Aerosol, spray Topical Liquid Topical 0.05 g/100g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 65.5 °C PhysProp boiling point (°C) 155 °C at 5.00E+00 mm Hg PhysProp logP 3.79 CHEM INSPECT TEST INST (1992) - Predicted Properties
Property Value Source Water Solubility 0.128 mg/mL ALOGPS logP 3.35 ALOGPS logP 3.62 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 7.07 Chemaxon pKa (Strongest Basic) -4.8 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 46.53 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 65.08 m3·mol-1 Chemaxon Polarizability 23.96 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9973 Blood Brain Barrier + 0.8691 Caco-2 permeable + 0.9258 P-glycoprotein substrate Non-substrate 0.6198 P-glycoprotein inhibitor I Non-inhibitor 0.7188 P-glycoprotein inhibitor II Non-inhibitor 0.8124 Renal organic cation transporter Non-inhibitor 0.8178 CYP450 2C9 substrate Non-substrate 0.703 CYP450 2D6 substrate Non-substrate 0.8915 CYP450 3A4 substrate Non-substrate 0.6542 CYP450 1A2 substrate Inhibitor 0.911 CYP450 2C9 inhibitor Non-inhibitor 0.907 CYP450 2D6 inhibitor Non-inhibitor 0.9437 CYP450 2C19 inhibitor Inhibitor 0.8995 CYP450 3A4 inhibitor Non-inhibitor 0.9258 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5 Ames test Non AMES toxic 0.9098 Carcinogenicity Non-carcinogens 0.8403 Biodegradation Not ready biodegradable 0.6452 Rat acute toxicity 1.6986 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9358 hERG inhibition (predictor II) Non-inhibitor 0.9337
Spectra
- Mass Spec (NIST)
- Download (8.57 KB)
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 162.3797539 predictedDarkChem Lite v0.1.0 [M-H]- 151.562924 predictedDarkChem Lite v0.1.0 [M-H]- 162.6872539 predictedDarkChem Lite v0.1.0 [M-H]- 153.5844 predictedDeepCCS 1.0 (2019) [M+H]+ 163.8159539 predictedDarkChem Lite v0.1.0 [M+H]+ 160.1214511 predictedDarkChem Lite v0.1.0 [M+H]+ 162.9261539 predictedDarkChem Lite v0.1.0 [M+H]+ 155.97981 predictedDeepCCS 1.0 (2019) [M+Na]+ 162.8818539 predictedDarkChem Lite v0.1.0 [M+Na]+ 167.0477522 predictedDarkChem Lite v0.1.0 [M+Na]+ 162.6925539 predictedDarkChem Lite v0.1.0 [M+Na]+ 162.03555 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Lipase with broad substrate specificity, catalyzing the hydrolysis of triacylglycerols (TAGs), diacylglycerols (DAGs), monoacylglycerols (MAGs), cholesteryl esters and retinyl esters (PubMed:15716583, PubMed:15955102, PubMed:19800417, PubMed:8812477). Shows a preferential hydrolysis of DAGs over TAGs and MAGs and preferentially hydrolyzes the fatty acid (FA) esters at the sn-3 position of the glycerol backbone in DAGs (PubMed:19800417). Preferentially hydrolyzes FA esters at the sn-1 and sn-2 positions of the glycerol backbone in TAGs (By similarity). Catalyzes the hydrolysis of 2-arachidonoylglycerol, an endocannabinoid and of 2-acetyl monoalkylglycerol ether, the penultimate precursor of the pathway for de novo synthesis of platelet-activating factor (By similarity). In adipose tissue and heart, it primarily hydrolyzes stored triglycerides to free fatty acids, while in steroidogenic tissues, it principally converts cholesteryl esters to free cholesterol for steroid hormone production (By similarity)
- Specific Function
- 1,2-diacylglycerol acylhydrolase activity
- Gene Name
- LIPE
- Uniprot ID
- Q05469
- Uniprot Name
- Hormone-sensitive lipase
- Molecular Weight
- 116596.715 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as a transcriptional activator or repressor
- Specific Function
- ATPase binding
- Gene Name
- PGR
- Uniprot ID
- P06401
- Uniprot Name
- Progesterone receptor
- Molecular Weight
- 98979.96 Da
References
- Schreurs RH, Sonneveld E, Jansen JH, Seinen W, van der Burg B: Interaction of polycyclic musks and UV filters with the estrogen receptor (ER), androgen receptor (AR), and progesterone receptor (PR) in reporter gene bioassays. Toxicol Sci. 2005 Feb;83(2):264-72. Epub 2004 Nov 10. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Antagonist
- General Function
- Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues (PubMed:19022849). Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation (PubMed:20812024). Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3
- Specific Function
- androgen binding
- Gene Name
- AR
- Uniprot ID
- P10275
- Uniprot Name
- Androgen receptor
- Molecular Weight
- 99187.115 Da
References
- Schreurs RH, Sonneveld E, Jansen JH, Seinen W, van der Burg B: Interaction of polycyclic musks and UV filters with the estrogen receptor (ER), androgen receptor (AR), and progesterone receptor (PR) in reporter gene bioassays. Toxicol Sci. 2005 Feb;83(2):264-72. Epub 2004 Nov 10. [Article]
- Araki N, Ohno K, Nakai M, Takeyoshi M, Iida M: Screening for androgen receptor activities in 253 industrial chemicals by in vitro reporter gene assays using AR-EcoScreen cells. Toxicol In Vitro. 2005 Sep;19(6):831-42. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3 (PubMed:17922032). Maintains neuronal survival in response to ischemic reperfusion injury when in the presence of circulating estradiol (17-beta-estradiol/E2) (By similarity)
- Specific Function
- 14-3-3 protein binding
- Gene Name
- ESR1
- Uniprot ID
- P03372
- Uniprot Name
- Estrogen receptor
- Molecular Weight
- 66215.45 Da
References
- Matsumoto H, Adachi S, Suzuki Y: [Estrogenic activity of ultraviolet absorbers and the related compounds]. Yakugaku Zasshi. 2005 Aug;125(8):643-52. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560)
- Specific Function
- DNA binding
- Gene Name
- ESR2
- Uniprot ID
- Q92731
- Uniprot Name
- Estrogen receptor beta
- Molecular Weight
- 59215.765 Da
References
- Matsumoto H, Adachi S, Suzuki Y: [Estrogenic activity of ultraviolet absorbers and the related compounds]. Yakugaku Zasshi. 2005 Aug;125(8):643-52. [Article]
Drug created at July 24, 2007 12:56 / Updated at October 21, 2024 12:39